Somatic POLE proofreading domain mutation, immune response and prognosis in colorectal cancer: a retrospective, pooled biomarker study
Background<br/> Precision cancer medicine depends on defining distinct tumour subgroups using biomarkers that may occur at very modest frequencies. One such subgroup comprises patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POL...
Asıl Yazarlar: | Domingo, E, Freeman-Mills, L, Rayner, E, Glaire, M, Briggs, S, Koelzer, V, Frangou, E, Dutton, P, Kerr, R, Kerr, D, Tomlinson, I, Church, D, EPICOLON consortium |
---|---|
Materyal Türü: | Journal article |
Baskı/Yayın Bilgisi: |
Lancet
2016
|
Benzer Materyaller
-
POLE proofreading domain mutation defines a subset of immunogenic colorectal cancers with excellent prognosis
Yazar:: Glaire, MA, ve diğerleri
Baskı/Yayın Bilgisi: (2016) -
POLE proofreading mutation, immune response and prognosis in endometrial cancer
Yazar:: Van Gool, I, ve diğerleri
Baskı/Yayın Bilgisi: (2015) -
POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer
Yazar:: Klenerman, P, ve diğerleri
Baskı/Yayın Bilgisi: (2015) -
Adjuvant treatment for POLE proofreading domain-mutant cancers: sensitivity to radiotherapy, chemotherapy, and nucleoside analogues
Yazar:: Van Gool, I, ve diğerleri
Baskı/Yayın Bilgisi: (2018) -
A panoply of errors: polymerase proofreading domain mutations in cancer
Yazar:: Rayner, E, ve diğerleri
Baskı/Yayın Bilgisi: (2016)